Rakesh Sharma, MD
Interventional Cardiology · Sebring, FLNPI 1114989134
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,987 of the $6,561 with a category attached, or 60.8%. 28 manufacturers reported payments, led by AstraZeneca at 39.8% of the total. Reporting peaked in 2019 at $4,216 and has fallen 83.0% since, to $718 in 2025. That places this record below the midpoint for interventional cardiology clinicians in FL, where the typical reported total is $7,973.
Across 169 payments — averaging $38.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Johnson & Johnson$802
- Novartis$702
- Amgen$391
- Abiomed$370
- Boston Scientific$301
- plus $1K from 22 others
Across 24 payments — averaging $15,994 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$278K
- Abbott$106K
- Abiomed$26
What the payments were for
- Speaking & faculty fees$2,15033%
- Travel & lodging$3385%
- Food & beverage$3,98761%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $2,614 |
| Johnson & Johnson | 20 | $802 |
| Novartis | 41 | $702 |
| Amgen | 12 | $391 |
| Abiomed | 5 | $370 |
| Boston Scientific | 12 | $301 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $220 |
| Abbott | 5 | $216 |
| Boehringer Ingelheim | 7 | $142 |
| Sanofi-aventis U.S. LLC | 8 | $123 |
| Merck | 6 | $96 |
| Pfizer | 5 | $94 |
| Medtronic(2 entities) | 5 | $78 |
| Astellas Pharma US Inc | 1 | $77 |
| Amarin Pharma, Inc. | 4 | $60 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Kestra Medical Technology Services, Inc. | 1 | $29 |
| Novo Nordisk | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Aegerion Pharmaceuticals, Inc. | 1 | $21 |
| Biosense Webster, Inc. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Vital Connect, Inc | 1 | $17 |
| Penumbra, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$461
- Repatha$227
- MitraClip$155
- GENERAL - STRUCTURAL HEART$117
- Impella$115
How this compares
$6,561 in reported general payments places this provider in the 40th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 230 | $223,265 |
| EntrestoSacubitril/Valsartan | 185 | $191,850 |
| XareltoRivaroxaban | 122 | $125,791 |
| BrilintaTicagrelor | 136 | $98,706 |
| Repatha SureclickEvolocumab | 84 | $69,950 |
| JardianceEmpagliflozin | 34 | $34,593 |
| MultaqDronedarone Hcl | 26 | $33,923 |
| FarxigaDapagliflozin Propanediol | 40 | $32,555 |
| Repatha SyringeEvolocumab | 20 | $22,475 |
| Praluent PenAlirocumab | 26 | $19,926 |
| NexletolBempedoic Acid | 13 | $11,874 |
| Fenofibrate | 14 | $6,674 |
| Metoprolol Succinate | 549 | $5,719 |
| Propafenone Hcl ErPropafenone Hcl | 12 | $5,084 |
| Rosuvastatin Calcium | 343 | $4,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $94 | $223,265230 claims |
| NovartisEntresto | $702 | $191,850185 claims |
| AstraZenecaBrilinta, Farxiga | $2,614 | $131,261176 claims |
| Johnson & JohnsonXarelto | $802 | $125,791122 claims |
| Boehringer IngelheimJardiance | $142 | $34,59334 claims |
| Sanofi-aventis U.S. LLCMultaq | $123 | $33,92326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Sebring
- Paul MichaelSebring$236K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.